Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

The purpose of the present study was to assess the effect of GLP-1, administered in combination with the thiazolidinedione, pioglitazone, on glucose, insulin, glucagon, free fatty acids (FFAs ...

The two incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide potentiate nutrient-dependent insulin secretion following meal ingestion. Metabolic ...

The report – which can be viewed here – highlights the following new medicines: 1) Novo Nordisk's Awiqli (LAI 287; insulin ... fixed-dose combination of an amylin analogue and GLP-1 agonist ...

A new study has found a combination of an SGLT-2 inhibitor drug ... of people globally living with diabetes will grow to at least 1.3 billion by 2050. “Diabetes has been considered as an ...

Liraglutide, a GLP ... basal insulin, continues to be a cornerstone of advanced diabetes management. In the future, these medications are expected to be improved through the use of combination ...

The plasma glucose concentration is held constant at basal levels by a variable glucose infusion. Whole-body insulin sensitivity ... to patients with type 1 diabetes in combination with rhIGFBP3 ...

Though you can hit speed bumps in your weight loss journey, Hone Health says there are minor tweaks you can make to get your ...